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OBJECTIVES We sought to evaluate the effectiveness and safety of thrombolytic therapy in stuck mitral
bileaflet heart valves in the absence of high-risk thrombi.
BACKGROUND Current recommendations for the thrombolytic treatment of stuck prosthetic mitral valves are
partially based on older valve models and inclusion of patients in whom high-risk thrombi
were either ignored or not sought for. The feasibility and safety of thrombolysis in bileaflet
models may be affected by the predilection of thrombi to catch the leaflet hinge.
METHODS We studied 12 consecutive patients (men/women 5 5/7, age 58.8 6 14.9 years) who
experienced one or more episodes of stuck bileaflet mitral valve over a 33-month period and
received thrombolytic therapy with streptokinase, urokinase or tissue-type plasminogen
activator. Transesophageal echocardiography was performed in all patients. Patients with
mobile or large (.5 mm) thrombi were excluded. Functional class at initial episode was I–II
in 4 patients (33.3%) and III–IV in 8 patients (66.6%).
RESULTS Patients receiving thrombolytic therapy achieved an overall 83.3% freedom from a repeat
operation or major complications (95% confidence interval 51.6–97.9%). Minor bleeding
occurred in three patients (25%) and allergic reaction in one (8.3%). Transient vague
neurologic complaints, without subjective findings, occurred in four patients (33.3%). Three
patients had one or more relapses within 5.2 6 3.1 months from the previous episode, and
readministration of thrombolytics was successful.
CONCLUSIONS In clinically stable patients with stuck bileaflet mitral valves and no high-risk thrombi,
thrombolysis is highly successful and safe, both in the primary episode and in recurrence. The
best thrombolytic regimen is yet to be established. (J Am Coll Cardiol 2000;35:1874–80) ©
2000 by the American College of Cardiology
Thrombosis is a well-recognized complication of prosthetic
heart valves and is associated with substantial morbidity and
mortality. Potential hazards include valve obstruction or
insufficiency, depending on the leaflet position, as well as
distal embolization. A repeat operation carries a substantial
risk, with mortality rate ranging from 10% to 15% in
selected series (1,2), which may be two- or three-fold higher
in critically ill patients. In 1971, Luluaga et al. (3) were the
first to report thrombolytic therapy with streptokinase in
stuck tricuspid valve. Three years later, Baille et al. (4)
reported the use of thrombolysis in a stuck left-sided (aortic)
valve. Nowadays, there are more than 200 reported cases of
thrombolysis of stuck left-sided valves, with an overall 82%
initial success rate, 12% thromboembolism, 5% to 10%
stroke, 6% death, 5% major bleeding and 11% recurrence
rate (1,5–11). The valve models involved in approximately
half of the cases are older ones (caged ball or single leaflet).
Information regarding bileaflet valves, which are currently
the preferred mechanical prosthetic valve models, is limited.
Moreover, bileaflet valves are of special interest because
their delicate mechanism may lead more easily to leaflet
immobilization, even with a relatively small clot. On the
other hand, if the offending clot is minor, thrombolysis may
be easier and safer. Therefore, we sought to explore the role
of thrombolysis in stuck bileaflet mitral valves based on our
own experience and a literature review.
METHODS
We sought the computerized database of the echocardiog-
raphy unit, the valvular clinic and the intensive care unit of
our institution, which is a tertiary referral medical center, for
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both the diagnoses “stuck mitral valve” and “thrombolysis”
from August 1996 to May 1999. Date of valve implantation,
its model, size and position were gathered from patients’
charts.
Patients’ symptoms were recorded, including symptom
duration, heart failure, expressed as New York Heart Asso-
ciation (NYHA) class, embolic phenomena (peripheral,
coronary, cerebral) anginal syndrome, palpitations and syn-
cope. Anticoagulation status was learned from admission
international normalized ratio (INR) values.
Definitions. Stuck valve. inability of valve leaflets to move
in full range fully, according to the manufacturer’s defini-
tions and previously studied normal range (12).
Thrombolytic course. Administration of a single thrombolytic
agent in its prescribed dosage.
Retreatment. Administration of an additional thrombolytic
agent in the same episode of stuck valve.
Valve reopening. Regaining full-range motion of valve leaf-
let.
Partial valve reopening. Achievement of improved but less
than full range of motion of valve leaflet.
Recurrence of stuck valve. A repeated episode of stuck valve
after complete reopening of its leaflets.
Fluoroscopy. Fluoroscopy was the mainstay of the evalua-
tion of leaflet mobility. The desired acquisition angle was
side/pivot view, with the disks parallel to the X-ray beams.
If pivot angle could not be accomplished, the closest
angulation was used.
Echocardiographic evaluation. All patients were evalu-
ated by an experienced echocardiographist using Hewlett-
Packard Sonos 1000 or Sonos 2000 echocardiography ma-
chine (Andover, Massachusetts), with 2.5 or 3.5 MHz
probe. Transthoracic echocardiogram (TTE) was per-
formed in all patients, using all standard views.
The following findings in TTE raised the suspicion of
stuck valve and mandated further studies (fluoroscopy and
transesophageal echocardiography [TEE]) for confirmation:
A) increased mean diastolic transvalvular gradients
(.6 mm Hg); B) failure to achieve at least one view
demonstrating movement of both leaflets.
Transesophageal echocardiography studies were per-
formed in all patients before thrombolysis, to exclude a
mobile large (.5 mm) thrombus, which is considered a
contraindication for thrombolysis in our institute (13).
Transesophageal echocardiography was performed using a
5 MHz multiplane probe. Attention was paid to leaflet
mobility, evidence of echogenic mass attached to the valve
or elsewhere in the left atrium and evidence of valve
regurgitation.
Treatment protocol. Intravenous heparin was given first in
selected cases according to the attending cardiologist, aim-
ing to achieve activated prothrombin time 3 1.5 to 2.0 of
the control. Thrombolysis was then given, using streptoki-
nase (STK), urokinase (UK) or recombinant tissue-type
plasminogen activator (tPA). Streptokinase was usually
given as a 30-min loading dose of 150,000 to 250,000 U,
followed by 100,000 U/h. Urokinase was given as a 30-min
loading dose of 4,400 U/kg, followed by 4,400 U/kg/h.
Both STK and UK were administered until valve reopening
or for at least 24 h. Tissue-type plasminogen activator was
usually administered as a 10-mg bolus followed by 90
additional mg in a continuous 3-h drip. The choice of
thrombolytic agent was subject to the decision of the
cardiologist in charge.
Intravenous heparin infusion was discontinued during
thrombolysis and was reinstituted after its termination.
Warfarin was administered concomitantly, to achieve target
(3.0–3.5) INR levels. Heparin was discontinued after two
therapeutic INR levels were achieved, 24 h apart. In
addition, all patients were given aspirin ($100 mg/day).
Evaluation of treatment outcome. Each patient underwent
TTE evaluation within 12 h from the start of thrombolytic
treatment and on a daily basis thereafter if full valve reopening
was not achieved. Clues for valve reopening were clear-cut
evidence of movement of both leaflets in a parallel fashion and
a substantial (.50%) decrease in transvalvular gradients. Con-
firmation of valve reopening was achieved by fluoroscopy,
which was performed in each patient within 24 h after
completion of each thrombolytic course.
Complications. Major bleeding was defined as any bleed-
ing that necessitated blood transfusion or was associated
with a decrease of 2 g/dl or more in blood hemoglobin
concentration. Otherwise, bleeding was termed minor. A
careful neurologic examination and brain computed tomog-
raphy were performed in any patient who had neurologic
complaints during or after the thrombolytic infusion. Fever,
shaking chills and generalized rash were considered indica-
tive of drug allergy, unless otherwise explained.
Follow-up after discharge. Each patient was discharged
with detailed instructions about the prompt anticoagulation
regimen and about heralding signs of stuck valve. Follow-up
in the valvular heart clinic included patient history, physical
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
FC 5 functional class
INR 5 international normalized ratio
NYHA 5 New York Heart Association
STK 5 streptokinase
TEE 5 transesophageal echocardiography
tPA 5 tissue-type plasminogen activator
TTE 5 transthoracic echocardiography
UK 5 urokinase
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examination and echocardiography at 1, 3, 6, 9 and 12
months after discharge and biannually thereafter. Fluoros-
copy was liberally instituted to rule out repeated restriction
of leaflet motion whenever TTE showed high transvalvular
gradients or leaflet motion seemed imperfect.
Statistics. Categorical data were compared by the chi-
square test. For the purpose of comparisons, the first
episode in each patient was analyzed. The 95% confidence
interval for success rate was retrieved from binomial distri-
bution tables (14). A p value of ,0.05 was considered
statistically significant.
RESULTS
Twelve patients experienced at least one episode of stuck
mitral valve handled by thrombolysis over a 33-month
period (8/96–5/99). During the study period there was only
a single episode of stuck valve in which surgery was the
recommended approach, due to large (.1 cm long) mobile
thrombi attached to the mitral valve. The total number of
thrombotic episodes treated with thrombolysis was 17
(including five episodes of rethrombosis, discussed separate-
ly). Selected patient characteristics are depicted in Table 1.
The predominant valve model was CarboMedics (Sulzer
Medica, Austin, Texas) which is the most frequently im-
planted valve model in our institution. One patient had a St.
Jude Medical (St. Paul, Minnesota) model. One patient
experienced one episode involving both mitral and tricuspid
valves. No case of stuck aortic valve was detected during the
study period. Valve sizes were 27 to 31 mm. The following
results apply to the first episode in each patient. Recurrences
are dealt with separately at the end of this section.
Clinical presentation (Table 1). The age during episodes
of stuck valve was 58.8 6 14.9 years (range 32–75 years). In
only four patients (33.3%) admission INR was .2.5.
Functional class (FC) was I to II in four patients (33.3%)
and III to IV in eight patients (66.7%)—two patients were
in FC III (16.7%) and six in FC IV (50%). All the patients
with congestive heart failure were initially stabilized with
diuretics, and digoxin was administered as necessary for
atrial fibrillation with rapid ventricular response. No patient
had resting symptoms by the time he/she received throm-
bolytic therapy. The symptom duration was ,7 days in four
patients (33.3%), while in the others it was either longer
(25% of patients) or they had no particular symptoms
(41.7%). There were no cases of peripheral cerebral or
coronary embolization at presentation. The diagnosis of
stuck valve was raised in all cases clinically or by routine
transthoracic echocardiography.
In three patients the diagnosis of stuck valve was made
during a routine visit to the valvular heart clinic. Three
patients were referred from the various internal medicine
departments, with initial FC III to IV. Five patients were
referred from other hospitals for a repeat surgery, but a
thrombolytic trial was attempted after reevaluation of the
cases. Four of these patients presented initially with FC III
to IV.
Treatment. Anticoagulation trial with full heparinization
was first attempted in six patients (one episode each) and
lasted 58 6 28.8 h (12 h to 96 h). Reopening of the valve
was not achieved in any patient by anticoagulant therapy
alone.
The overall results are shown in Table 2. Valve reopening
(full or partial) was achieved in 10/12 patients (83.3%, 95%
confidence interval 51.6% to 97.9%), obviating the need for
a repeat surgery. One patient was discharged with only
partial resolution of leaflet motion. Two patients who failed
Table 1. Patients’ Characteristics
Characteristic Result*
Number of patients 12
Age (yrs) 58.8 6 14.9 (32–75)
Gender (M/F) 5/7
Baseline rhythm
Sinus rhythm 7 (58.3%)
Atrial fibrillation 5 (41.7%)
Time from valve insertion to an
episode of stuck valve
(months)
35.4 6 27.8 (3–89)
Symptom duration
,7 days 4 (33.3%)
7–30 days 3 (25%)
Incidental finding 5 (41.7%)
Initial functional class
I–II 4 (33.3%)
III 2 (16.7%)
IV 6 (50%)
INR on admission
,2.5 8 (66.7%)
$2.5 4 (33.3%)
*numbers in parentheses denote percentage of patients.
INR 5 international normalized ratio.
Table 2. Overall Results of Thrombolysis in 12 Patients With
Stuck Mitral Valves
Parameter Result*
Clinical success (surgery avoided) 10/12 (83.3%)
Referred to surgery 2/12 (16.7%)
Mortality 1/12 (8.3%)
Thrombolysis 0
Surgery 1/2 (50%)
Relapse of stuck valve 3/10 (30%)
Success rate in relapse 3/3 (100%)
Major complications 0
Minor complications 8 (66.6%)
Minor bleeding 3 (25%)
Vague neurologic complaints 4 (33.3%)
Allergic reaction 1 (8.3%)
*Results concerning 12 patients. In recurrence, only 10 patients are counted because
two patients underwent a repeat operation.
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to respond to thrombolysis were referred for a repeat
operation. One of them died three days after mitral valve
replacement due to pump failure. Aortic valve replacement
was also conducted in this patient due to entrapment of an
aortic cusp by a suture from the previous surgery. The
second patient experienced acute renal failure, which even-
tually resolved. Both patients who needed surgery for failed
thrombolysis had a combination of ingrown fibrous tissue
and thrombi of various ages.
Twenty thrombolytic courses were given (Table 3). The
mean number of thrombolytic courses per episode was
1.75 6 0.62 (range 1–3). Tissue-type plasminogen activator
was the most frequently agent used (12/20 courses—60%),
and it gained complete resolution in six courses (50%). Two
additional courses of tPA culminated in partial reopening,
but reopening was finally achieved after a repeated course.
The duration of STK or UK infusion in the four patients
(six courses) who had no adverse effects was .12 h in all
cases (14–84 h, mean 40.5 6 29 h). Among these, only one
course lasted ,24 h.
Repeated thrombolytic courses. Repeated thrombolytic
courses during the same episode were given in eight courses:
seven patients received a single additional course, and one
patient received two additional courses. Six patients were
switched to another agent due to failure to achieve valve
reopening. Among these six patients, three cases regained
full leaflet motion after a repeated course. In two cases the
reason for repeated course was an adverse reaction, and all
full success was achieved in both.
Adverse reactions. There were no major complications
(100% freedom from major complications, 95% confidence
interval 73.5–100%). Minor bleeding occurred in three
patients: subcutaneous bleeding, gross hematuria and bleed-
ing to hypopharynx (after TEE)—one case each. Allergic
reactions occurred in one patient treated with STK. Four
patients experienced dizziness and vague neurologic com-
plaints. Neurologic examination and brain computed to-
mography did not reveal any neurologic deficit or intracra-
nial hemorrhage.
Mode of diagnosis of valve reopening. In addition to
TTE and fluoroscopy (which were performed to confirm
valve reopening in all the study patients), TEE was per-
formed after thrombolysis in only three patients with failed
mitral reopening.
The mean transvalvular gradient before therapy was
14.5 6 6.2 mm Hg (range 8–28 mm Hg). It decreased to
4.1 6 1.7 mm Hg (range 2–7 mm Hg) after complete
resolution of leaflet motion was achieved, 9 and 6 mm Hg
in the cases of partial resolution and 19 and 6.7 mm Hg in
two cases of treatment failure.
Influence of symptom duration. There was no statistically
significant difference in the success rate among patients with
symptoms lasting ,7 days, 7 to 30 days and asymptomatic
patients.
Visualization of a thrombus—relation to success and
complication. Small (,5 mm) echogenic masses consis-
tent with thrombi were observed in seven (58.3%) patients
(one episode each, all in their first episode). Their greater
dimension was 2.2 6 1.1 mm (0.9–4.0 mm). Thrombolysis
was successful in 5/7 patients (71.4%) when thrombi were
visualized and in 5/5 patients (100%) when thrombi were
not visualized (p value 5 not significant). The vague
neurologic symptoms were evenly distributed between these
two groups (two patients each) (p value 5 not significant).
Recurrent episodes of stuck valve. Three patients (30% of
patients, after excluding two patients who were referred for
surgery) experienced a total of five recurrent episodes of
stuck valve after successful thrombolytic courses: two pa-
tients had one relapse each (both were in FC III, and one
patient experienced three relapses (FC II in all). The mean
time to relapse was 5.2 6 3.1 months (range 3–10 months).
Reestablishment of thrombolysis (tPA in all cases) resulted
in full resolution of leaflet movement in two patients (one
episode each). In the third patient, a full resolution was
achieved twice, but, on his third relapse, he was discharged
with only a partial resolution. Follow-up time for the five
patients who responded by full valve reopening to throm-
bolysis and did not experience recurrent episodes of stuck
valve was 9.6 6 10.8 months (range 1–28 months).
DISCUSSION
Bileaflet valves are the mechanical valves of choice at the
present. Data focusing on these valve models with respect to
valve thrombosis is emerging only in the last decade
Table 3. Outcome of Treatment According to Thrombolytic Agent (1st Episode)
Agent
Success
Failure
Discontinuation
Due to Adverse
Effects TotalFull Partial
STK 1 1 1 2 5
UK 1 1 1 — 3
tPA 6 2 3 1 12
Total 8 4 5 3 20
STK 5 streptokinase; tPA 5 tissue-type plasminogen activator; UK 5 urokinase.
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(1,5–11,13,15). This study enlightens some aspects unique
to thrombosed bileaflet valves and their implications on the
feasibility and safety of thrombolysis.
Pathology in stuck bileaflet valves. Different prosthetic
valve models may vary in their propensity for thrombosis,
the relative interrelations and proportion of ingrowth tissue
and thrombus, the amount of thrombus needed to disturb
leaflet motion and the vulnerable zones within the valve.
Data on the pathologic findings in patients with stuck
bileaflet valves are sparse. The most extensive data come
from Deviri et al. (2), who studied 112 cases of explanted
thrombosed valves, of which 41 (36.6%) were bileaflet (St.
Jude Medical). Among these 41 patients, in 30 (73.2%) the
thrombus was at the hinge site, causing impairment of both
leaflet motion. Vitale et al. (1) studied 87 explanted throm-
botic prosthetic valves, of which only 12 (13.8%) were
bileaflet (six CarboMedics, four Jyros [Medos-Western BV,
Amsterdam, the Netherlands], two St. Jude Medical).
Pannus formation was identified in 5/12 cases (41.7%) and
was eccentric in two and concentric in three. The specific
location of the pannus or thrombi and the number of leaflets
involved were not specified in that study.
It seems that the amount of thrombotic material needed to
cause interruption of leaflet motion in bileaflet valves is
minimal, especially if it catches the hinge of the valve. A small
thrombus may even entrap the hinges of both leaflets (2,6).
Thrombus size and feasibility of thrombolysis. There are
conflicting opinions regarding the size of the thrombus and
how it should affect the feasibility of thrombolysis. Hurrell
et al. (13) considered a large (.5 mm) left sided thrombus
as a contraindication to thrombolysis. Lengyel et al. (10)
considered a large thrombus as a relative contraindication to
thrombolysis, but no cut-off point was given. On the other
side, Vitale et al. (8) considered a visible clot on TEE as one
of the diagnostic criteria essential to the establishment of
prosthetic valve thrombosis. Our policy is to handle stuck
valve by thrombolysis, unless a large ($5 mm) thrombus is
visualized. Visualization of the thrombus in not considered
an essential prerequisite for the diagnosis.
Choice of the thrombolytic agent. Previous studies con-
sidered all thrombolytic agents as equally effective in the
resolution of prosthetic valve thrombosis (10,13,15). How-
ever, the results with tPA were retrieved from a small
number of patients (less than 20 patients in total). Our study
confirms the effectiveness and safety of tPA, which was the
major thrombolytic agent used by our group. Comparison
with the other agents we used is irrelevant due to the small
number of courses and the nonrandomized fashion in which
the agents were chosen. Streptokinase is associated with a
generalized thrombolytic state, and, if cardiac surgery is
indicated on an emergent or urgent basis, it may be
associated with significant difficulties in bleeding control
and increased blood consumption (16,17). Tissue-type plas-
minogen activator is more fibrin specific and was associated
with less postoperative blood requirement in patients un-
dergoing coronary artery bypass grafting (CABG) within
24 h of tPA infusion (18,19). Thus, if thrombolysis fails and
the patient needs an emergent operation, bleeding control
may be achieved more effectively after tPA than after STK.
Another argument for the use of tPA is its ability to dissolve
a fresh cerebral embolus (20). It is possible that the vague
neurologic complaints in four of our patients (three of
whom complained during tPA therapy) reflected cerebral
embolization of thrombotic material, which quickly dis-
solved without clinical residua.
We did not measure the exact time to reopening after
administration of UK or STK, which were given in a
continuous infusion. Tissue-type plasminogen activator, on
the other side, was administered in a short, predefined
period, and TTE was usually done at the end of drug
infusion. It is our impression that tPA was faster to achieve
valve reopening, which may be crucial in unstable patients.
A prospective study is warranted to clarify this point.
Recurrence. The recurrence rate observed in our study is
high (3/10 patients [30%]). In two patients it can be
attributed to poor compliance with anticoagulant therapy,
despite meticulous patient guidance. Our high index of
suspicion may also account for the high recurrence rate. We
advocate fluoroscopy in each patient with prosthetic mitral
or tricuspid valve in whom we cannot achieve at least one
view demonstrating movement of both leaflets on trans-
thoracic echocardiogram or when a high (.6 mm Hg) mean
transvalvular gradient is measured. Even older generation
echocardiography machines identified both mitral leaflets in
85% of patients (21), and with newer equipment the odds
should be higher. Moreover, patients with a previous history
of stuck valve are frequently checked (at least every three
months in the first year). Thus, recurrence can be detected
during early stages before the development of overt heart
failure.
Absence of disabling embolic events: the role of TEE.
The lack of disabling embolic events in our patients reflects
the careful selection of patients, i.e., the exclusion of
patients with large or pedunculated mobile thrombi. In
addition, our policy is to advocate thrombolysis as the first
line of therapy in stuck valve, even in mildly symptomatic or
low-risk patients. In contrast, the two largest series (engulf-
ing nearly half of the patients receiving thrombolysis for
stuck mitral valve reported in the literature) included pa-
tients either on the basis of advanced heart failure or those
who were so critically ill that the operative mortality was
considered prohibitive (5,7). Above all, we believe that TEE
should always be performed before thrombolysis in left-
sided valves to exclude large thrombi. In a literature review
of 182 left-sided thrombotic episodes, there were 23 epi-
sodes of transient or permanent neurologic damage or
peripheral emboli (12.6%) (9). Fourteen of these episodes
were taken from a single study (5) in which TEE was
performed only in 11/74 episodes (14.9%): 9/41 (22.0%) in
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stuck mitral valve and 2/33 (6.1%) in stuck aortic valve. In
the other studies altogether, the above-mentioned compli-
cations occurred in 9/108 (8.3%), with only two cases of
permanent neurologic damage (1.9%), one of which oc-
curred when thrombolysis was given, despite the visualiza-
tion of a mobile thrombus in TEE (22). We believe that the
high rate of cerebral and peripheral emboli reported in the
literature reflects poor patient selection, that is, inclusion of
patients in whom large left-sided thrombi were not excluded
by TEE.
Comparison with previous studies. Data from the main
reports on thrombolytic therapy in stuck bileaflet mitral
valves are shown in Table 4. It is evident that the outcome
in this study ranks among the best reported in the current
literature. These results can be partially attributed to our
policy to always give at least one additional thrombolytic
trial after the first course failed (completely or partially).
Had we sent each patient with failed or suboptimal first
thrombolytic course to surgery, an additional five patients
would have been operated on, reducing the attractiveness of
this modality.
We did not observe stuck aortic valve during the study
period. Thus, conclusions should be limited to mitral valves.
Study limitations. The thrombolytic medications were
chosen on an individual basis and not in a randomized
fashion and were often subject to personal experience and
drug availability. Thus, head-to-head comparison of the
various thrombolytic medications and regimens cannot be
made.
The timing of valve reopening could not be precisely
measured. Repeated TTE was usually made upon comple-
tion of tPA infusion (3 h after its start). However, when
patients received STK or UK, the time-scale for the
determination valve status was wider (within 12 h from the
start of infusion). Thus, the time to reopening could be less
precisely made.
The number of patients in this study is limited, although
it ranks amongst the highest in published series (Table 4).
Thus, it is under-powered to detect statistically significant
differences from previously published series. Nevertheless,
our results are encouraging and should be substantiated by
additional series.
Conclusions. In patients with stuck bileaflet mitral valves
without large clots, thrombolysis offers a valid alternative to
surgery with a high success rate and minimal complications.
This therapy may be implemented in a wide variety of
patients, regardless of symptom duration or severity, except
for hemodynamically compromised patients who are other-
wise good surgical candidates who may not withstand the
delay to surgery. Visualization of a thrombus is not a
prerequisite for thrombolysis. More than a single therapeu-
tic trial is sometimes needed to fully reopen the stuck
leaflets. Readministration of thrombolysis for recurrence is
highly successful as well. Since recurrent episodes may beTa
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subclinical, frequent follow-up echocardiograms are advo-
cated after a successful thrombolysis, and fluoroscopy should
be liberally instituted to evaluate leaflet motion. Further
studies are required to substantiate the encouraging results
of our study and to establish the best thrombolytic regimens.
Reprint requests and correspondence: Dr. Alex Sagie, Depart-
ment of Cardiology, Rabin Medical Center, Beilinson Campus,
Petah-Tiqva, 49100 Israel.
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